B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 13.9 HKD 17% Market Closed
Market Cap: 5.6B HKD

Intrinsic Value

The intrinsic value of one Biocytogen Pharmaceuticals Beijing Co Ltd stock under the Base Case scenario is 13.28 HKD. Compared to the current market price of 13.9 HKD, Biocytogen Pharmaceuticals Beijing Co Ltd is Overvalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
13.28 HKD
Overvaluation 4%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation History
Biocytogen Pharmaceuticals Beijing Co Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Biocytogen Pharmaceuticals Beijing Co Ltd
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for Biocytogen Pharmaceuticals Beijing Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

No research report yet

Want a deep‑dive on Biocytogen Pharmaceuticals Beijing Co Ltd?
Request it below and we’ll move it up the queue.

Request This Report
What’s Inside the Report:
Whether it’s a smart buy right now
If the stock is undervalued
Its long-term growth potential
Whether the dividend is safe
How it compares to peers
How strong its moat is
Whether management can be trusted
You Can Read These Reports Right Now
Dive in while we’re working on Biocytogen Pharmaceuticals Beijing Co Ltd’s research
View All Researches
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
CN
Biotechnology
Market Cap
5.6B HKD
IPO
Sep 1, 2022
CN
Biotechnology
Market Cap
5.6B HKD
IPO
Sep 1, 2022
Price
HK$false
EPS
ÂĄfalse
AI Assistant
AI Assistant
Ask me anything about Biocytogen Pharmaceuticals Beijing Co Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Biocytogen Pharmaceuticals Beijing Co Ltd

Balance Sheet Decomposition
Biocytogen Pharmaceuticals Beijing Co Ltd

Current Assets 816.5m
Cash & Short-Term Investments 403.9m
Receivables 229.6m
Other Current Assets 183.1m
Non-Current Assets 1.6B
Long-Term Investments 159m
PP&E 1.3B
Intangibles 20.7m
Other Non-Current Assets 69.6m
Efficiency

Free Cash Flow Analysis
Biocytogen Pharmaceuticals Beijing Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Biocytogen Pharmaceuticals Beijing Co Ltd

Revenue
980.5m CNY
Cost of Revenue
-218.9m CNY
Gross Profit
761.5m CNY
Operating Expenses
-611m CNY
Operating Income
150.5m CNY
Other Expenses
-117m CNY
Net Income
33.5m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

Biocytogen Pharmaceuticals Beijing Co Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive ROIC
33/100
Profitability
Score

Biocytogen Pharmaceuticals Beijing Co Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Biocytogen Pharmaceuticals Beijing Co Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
50/100
Solvency
Score

Biocytogen Pharmaceuticals Beijing Co Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Biocytogen Pharmaceuticals Beijing Co Ltd

Wall Street analysts forecast Biocytogen Pharmaceuticals Beijing Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Biocytogen Pharmaceuticals Beijing Co Ltd is 15.17 HKD with a low forecast of 13.62 HKD and a high forecast of 17.06 HKD.

Lowest
Price Target
13.62 HKD
2% Downside
Average
Price Target
15.17 HKD
9% Upside
Highest
Price Target
17.06 HKD
23% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Biocytogen Pharmaceuticals Beijing Co Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for Biocytogen Pharmaceuticals Beijing Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one Biocytogen Pharmaceuticals Beijing Co Ltd stock?

The intrinsic value of one Biocytogen Pharmaceuticals Beijing Co Ltd stock under the Base Case scenario is 13.28 HKD.

Is Biocytogen Pharmaceuticals Beijing Co Ltd stock undervalued or overvalued?

Compared to the current market price of 13.9 HKD, Biocytogen Pharmaceuticals Beijing Co Ltd is Overvalued by 4%.

Back to Top